Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN  
145.38
-0.33 (-0.23%)
Products, Regulatory

Biohaven Provides Update On Phase 3 Clinical Trial Evaluating Troriluzole For Spinocerebellar Ataxia (SCA)

Published: 05/23/2022 11:58 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (sca).
Biohaven Pharmaceutical - Primary Endpoint Did Not Reach Statistical Significance in Overall Sca Population.
Biohaven Pharmaceutical Holding Company Ltd - There Was Less Than Expected Disease Progression Over Course of Study.
Biohaven Pharmaceutical - Post Hoc Analyses by Sca Genotype Suggest Early, Sustained Improvements in F-sara Over 48 Weeks for Sca3 Patients Treated With Troriluzole Versus Placebo.